NCT07738614
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
StatusActive, Not Recruiting
PhasePhase 1
SponsorEli Lilly and Company
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 9 words
- Enrollment closed, study ongoing
- Site details revised at 2 of 2 sites
- Notable Recruitment opened
- Start date changed from estimate of Jul 2026 to Jul 31, 2026
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Acetaminophen Area Under the Concentration Versus Time Curve (AUC)
Timeframe: Baseline to Day 65
Acetaminophen Maximum Observed Concentration (Cₘₐₓ)
Timeframe: Baseline to Day 65
Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ)
Timeframe: Baseline to Day 65
Secondary (2)
Eloralintide AUC
Eloralintide Cₘₐₓ
Arms and interventions
Eloralintide Cohort 1Experimental
Eloralintide administered subcutaneously (SC)
Eloralintide Cohort 2Experimental
Eloralintide administered SC
Eloralintide Cohort 3Experimental
Eloralintide administered SC
Eloralintide Cohort 4Experimental
Eloralintide administered SC
PlaceboPlacebo comparator
Placebo administered SC
Drugs: Eloralintide, Placebo, Acetaminophen
Sites
2 sites in 2 countries
Singapore 1, United States 1